FDA-approved Treatments
Experimental Treatments
Top New Articles
 Google Custom Search
Certain Maternal and Child HLA Patterns Increase Risk of Vertical HIV Transmission

By Liz Highleyman

South African mother with HIV/AIDS who has access to life-saving treatment.
It is well known that without prophylactic antiretroviral therapy, HIV may be transmitted from mothers to their babies during gestation, delivery, or breast-feeding. However, besides HIV viral load, the factors that increase the risk of perinatal transmission are not fully understood.

In a study described in the April 15, 2008 Journal of Infectious Diseases, an American and African research team looked at associations between maternal and child human leukocyte antigen (HLA) patterns and likelihood of HIV transmission.

The HLA system, or major histocompatibility complex, is a group of genes that play a role in immune response. Each individual carries two versions of HLA, which may either be the same (homozygous) or different (heterozygous). Further, mothers and their babies may either have matching (concordant) or dissimilar (discordant) HLA patterns.

In the present study, the researchers set out to test the hypothesis that maternal HLA homozygosity and mother-child HLA concordance may increase the risk of vertical HIV transmission by reducing infant immune responses.
They analyzed HLA patterns in 277 mother-infant pairs in a Kenyan perinatal cohort receiving prenatal zidovudine (AZT; Retrovir) to reduce the risk of HIV transmission. HLA concordance was scored as the number of shared class I alleles. Relative risk estimates were adjusted for maternal HIV viral load.

Results

Among 277 mother-infant pairs, a total of 58 infants (21%) were infected with HIV:

in utero: 21 (36%);
peripartum (during delivery): 26 (45%);
via breast-feeding: 11 (19%).

As HLA concordance increased, there was a significant rise in the risk of HIV transmission overall (adjusted hazard ratio [AHR] 1.3), in utero (AHR 1.72), and via breast-feeding (AHR 1.6) (all P = .04).

Women with HLA homozygosity had higher plasma HIV RNA levels at 32 weeks of gestation (5.1 vs 4.8 log10 copies/mL; P = .03).

HLA homozygous mothers had an increased risk of transmitting HIV overall (AHR 1.7; P = .03) and via breast-feeding (AHR 5.8; P = .002).

Conclusion

"The risks of overall, in utero, and breast milk HIV-1 transmission increased with HLA concordance and homozygosity," the investigators concluded. "The increased risk may be due to reduced alloimmunity or less diverse protective immune responses."

University of Washington, Seattle, WA; Laboratory of Genomic Diversity, Science Applications International Corporation-Frederick, National Cancer Institute-Frederick, Frederick, MD; University of Nairobi, Nairobi, Kenya; Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK.

4/18/08

Reference
RD Mackelprang, G John Stewart, M Carrington, and others. Maternal HLA Homozygosity and Mother Child HLA Concordance Increase the Risk of Vertical Transmission of HIV 1. Journal of Infectious Diseases 19798): 1156-1161. April 15, 2008.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors (PIs)
Note: Most PIs are now used
in combination with low-dose
ritonavir (Norvir)
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir )
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
Viracept
Viracept (nelfinavir)
Nucleoside / Nucleotide
Reverse Transcriptase
Inhibitors (NRTIs)
Combivir
Combivir (zidovudine + lamivudine)
Epivir
Epivir (lamivudine; 3TC)
Emtriva
Emtriva (emtricitabine; FTC)
Epzicom
Epzicom (abacavir + lamivudine)
Retrovir
Retrovir (zidovudine; AZT)
Trizivir
Trizivir (abacavir + zidovudine +lamivudine)
Truvada
Truvada  (tenofovir + emtricitabine)
Videx
Videx (didanosine; ddI)
Viread
Viread (tenofovir)
Zerit
Zerit (stavudine; d4T)
Ziagen
Ziagen (abacavir)
non Nucleoside 
Reverse Transcriptase
 Inhibitors
(nNRTIs)
Rescriptor
Intelence (etravirine)
Rescriptor
Rescriptor (delavirdine)
Sustiva
Sustiva (efavirenz)
Viramune
Viramune (nevirapine)
Entry / Fusion Inhibitors
Fuzeon (enfuvirtide)
Selzentry/Celsentri ( maraviroc)
Fixed-dose Combinations
Atripla
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir
Combivir (zidovudine + lamivudine)
Trizivir
Trizivir (abacavir + zidovudine + lamivudine)
Truvada
Truvada (tenofovir + emtricitabine)
Integrase Inhibitors
Isentress (raltegravir)